These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 18396633)

  • 1. [Progress in treatment of metastatic tumors in the bone by bisphosphonate].
    Dong M; Chen XP; Feng FY
    Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):801-3. PubMed ID: 18396633
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacotherapy of bone metastases in breast cancer patients.
    Petrut B; Simmons C; Broom R; Trinkaus M; Clemons M
    Expert Opin Pharmacother; 2008 Apr; 9(6):937-45. PubMed ID: 18377337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone continuum of cancer.
    Lipton A
    Am J Clin Oncol; 2010 Jun; 33(3 Suppl):S1-7. PubMed ID: 20526089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How can we improve the treatment of bone metastases further?
    Coleman RE
    Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S7-13. PubMed ID: 9801853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer: bisphosphonate therapy for metastatic bone disease.
    Body JJ
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6258s-6263s. PubMed ID: 17062710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
    J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical implications of bisphosphonate for bone metastases of prostate cancer].
    Kitagawa Y; Konaka H; Mizokami A; Namiki M
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():356-9. PubMed ID: 18161131
    [No Abstract]   [Full Text] [Related]  

  • 8. [Bisphosphonate treatment against breast cancer with bone metastases].
    Kohno N
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():575-81. PubMed ID: 17682213
    [No Abstract]   [Full Text] [Related]  

  • 9. Bisphosphonates--role in cancer therapies.
    Mehrotra B
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):19-26. PubMed ID: 19371811
    [No Abstract]   [Full Text] [Related]  

  • 10. Bisphosphonates for care and cure.
    Body JJ
    Eur J Cancer; 2009 Sep; 45 Suppl 1():396-7. PubMed ID: 19775644
    [No Abstract]   [Full Text] [Related]  

  • 11. [Bisphosphonate against patients with hormone refractory prostate cancer].
    Shinohara N
    Nihon Rinsho; 2011 Jun; 69 Suppl 5():576-80. PubMed ID: 22208047
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy.
    Vogel CL; Yanagihara RH; Wood AJ; Schnell FM; Henderson C; Kaplan BH; Purdy MH; Orlowski R; Decker JL; Lacerna L; Hohneker JA
    Oncologist; 2004; 9(6):687-95. PubMed ID: 15561812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approaches to managing bone metastases from breast cancer: the role of bisphosphonates.
    Mystakidou K; Katsouda E; Stathopoulou E; Vlahos L
    Cancer Treat Rev; 2005 Jun; 31(4):303-11. PubMed ID: 16039956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
    Marx RE; Sawatari Y; Fortin M; Broumand V
    J Oral Maxillofac Surg; 2005 Nov; 63(11):1567-75. PubMed ID: 16243172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Biphosphonates and prostatic cancer. A survey of a Cochrane review].
    Jønler M; Borre M
    Ugeskr Laeger; 2007 Nov; 169(47):4058-61. PubMed ID: 18078660
    [No Abstract]   [Full Text] [Related]  

  • 17. Bisphosphonates: reducing the risk of skeletal complications from bone metastasis.
    Costa L
    Breast; 2007 Dec; 16 Suppl 3():S16-20. PubMed ID: 18032044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sowing the soil for cure? Results of the ABCSG-12 trial open a new chapter in the evolving adjuvant bisphosphonate story in early breast cancer.
    Bedard PL; Body JJ; Piccart-Gebhart MJ
    J Clin Oncol; 2009 Sep; 27(25):4043-6. PubMed ID: 19652062
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical study of bisphosphonates for bone metastasis in breast cancer].
    Yamada K; Kohno N
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():352-5. PubMed ID: 18161130
    [No Abstract]   [Full Text] [Related]  

  • 20. Case 2. Osteonecrosis of the jaws associated with bisphosphonate therapy.
    Mignogna MD; Fedele S; Lo Russo L; Ciccarelli R; Lo Muzio L
    J Clin Oncol; 2006 Mar; 24(9):1475-7. PubMed ID: 16549843
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.